The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Anti-Diabetic Drugs-Global Market Insights and Sales Trends 2024
Synopsis
The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.
The global Anti-Diabetic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Anti-Diabetic Drugs in various end use industries. The expanding demands from the Type I Diabetes, Type II Diabetes and Others,, are propelling Anti-Diabetic Drugs market. Biguanides, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sulfonylureas segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-Diabetic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-Diabetic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-Diabetic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-Diabetic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-Diabetic Drugs covered in this report include Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Sanofi and Teva Pharmaceutical Industries, etc.
The global Anti-Diabetic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astra Zeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Teva Pharmaceutical Industries
Global Anti-Diabetic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-Diabetic Drugs market, Segment by Type:
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
Dipeptidyl Peptidase IV Inhibitors
α-Glucosidase Inhibitors
Global Anti-Diabetic Drugs market, by Application
Type I Diabetes
Type II Diabetes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Anti-Diabetic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.
The global Anti-Diabetic Drugs market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Anti-Diabetic Drugs in various end use industries. The expanding demands from the Type I Diabetes, Type II Diabetes and Others,, are propelling Anti-Diabetic Drugs market. Biguanides, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Sulfonylureas segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Anti-Diabetic Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Anti-Diabetic Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Anti-Diabetic Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Anti-Diabetic Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Anti-Diabetic Drugs covered in this report include Astra Zeneca, Boehringer Ingelheim, Eli Lilly, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Sanofi and Teva Pharmaceutical Industries, etc.
The global Anti-Diabetic Drugs market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astra Zeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Teva Pharmaceutical Industries
Global Anti-Diabetic Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Anti-Diabetic Drugs market, Segment by Type:
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
Dipeptidyl Peptidase IV Inhibitors
α-Glucosidase Inhibitors
Global Anti-Diabetic Drugs market, by Application
Type I Diabetes
Type II Diabetes
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Anti-Diabetic Drugs companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Anti-Diabetic Drugs
1.1 Anti-Diabetic Drugs Market Overview
1.1.1 Anti-Diabetic Drugs Product Scope
1.1.2 Anti-Diabetic Drugs Market Status and Outlook
1.2 Global Anti-Diabetic Drugs Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Anti-Diabetic Drugs Market Size by Region (2018-2029)
1.4 Global Anti-Diabetic Drugs Historic Market Size by Region (2018-2023)
1.5 Global Anti-Diabetic Drugs Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Anti-Diabetic Drugs Market Size (2018-2029)
1.6.1 North America Anti-Diabetic Drugs Market Size (2018-2029)
1.6.2 Europe Anti-Diabetic Drugs Market Size (2018-2029)
1.6.3 Asia-Pacific Anti-Diabetic Drugs Market Size (2018-2029)
1.6.4 Latin America Anti-Diabetic Drugs Market Size (2018-2029)
1.6.5 Middle East & Africa Anti-Diabetic Drugs Market Size (2018-2029)
2 Anti-Diabetic Drugs Market by Type
2.1 Introduction
2.1.1 Biguanides
2.1.2 Sulfonylureas
2.1.3 Meglitinides
2.1.4 Thiazolidinediones
2.1.5 Dipeptidyl Peptidase IV Inhibitors
2.1.6 α-Glucosidase Inhibitors
2.2 Global Anti-Diabetic Drugs Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Anti-Diabetic Drugs Historic Market Size by Type (2018-2023)
2.2.2 Global Anti-Diabetic Drugs Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Anti-Diabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Anti-Diabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Anti-Diabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Anti-Diabetic Drugs Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Anti-Diabetic Drugs Revenue Breakdown by Type (2018-2029)
3 Anti-Diabetic Drugs Market Overview by Application
3.1 Introduction
3.1.1 Type I Diabetes
3.1.2 Type II Diabetes
3.1.3 Others
3.2 Global Anti-Diabetic Drugs Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Anti-Diabetic Drugs Historic Market Size by Application (2018-2023)
3.2.2 Global Anti-Diabetic Drugs Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Anti-Diabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Anti-Diabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Anti-Diabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Anti-Diabetic Drugs Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Anti-Diabetic Drugs Revenue Breakdown by Application (2018-2029)
4 Anti-Diabetic Drugs Competition Analysis by Players
4.1 Global Anti-Diabetic Drugs Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Anti-Diabetic Drugs as of 2022)
4.3 Date of Key Players Enter into Anti-Diabetic Drugs Market
4.4 Global Top Players Anti-Diabetic Drugs Headquarters and Area Served
4.5 Key Players Anti-Diabetic Drugs Product Solution and Service
4.6 Competitive Status
4.6.1 Anti-Diabetic Drugs Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 Astra Zeneca
5.1.1 Astra Zeneca Profile
5.1.2 Astra Zeneca Main Business
5.1.3 Astra Zeneca Anti-Diabetic Drugs Products, Services and Solutions
5.1.4 Astra Zeneca Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.1.5 Astra Zeneca Recent Developments
5.2 Boehringer Ingelheim
5.2.1 Boehringer Ingelheim Profile
5.2.2 Boehringer Ingelheim Main Business
5.2.3 Boehringer Ingelheim Anti-Diabetic Drugs Products, Services and Solutions
5.2.4 Boehringer Ingelheim Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.2.5 Boehringer Ingelheim Recent Developments
5.3 Eli Lilly
5.3.1 Eli Lilly Profile
5.3.2 Eli Lilly Main Business
5.3.3 Eli Lilly Anti-Diabetic Drugs Products, Services and Solutions
5.3.4 Eli Lilly Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.3.5 Johnson & Johnson Recent Developments
5.4 Johnson & Johnson
5.4.1 Johnson & Johnson Profile
5.4.2 Johnson & Johnson Main Business
5.4.3 Johnson & Johnson Anti-Diabetic Drugs Products, Services and Solutions
5.4.4 Johnson & Johnson Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.4.5 Johnson & Johnson Recent Developments
5.5 Merck
5.5.1 Merck Profile
5.5.2 Merck Main Business
5.5.3 Merck Anti-Diabetic Drugs Products, Services and Solutions
5.5.4 Merck Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.5.5 Merck Recent Developments
5.6 Novartis
5.6.1 Novartis Profile
5.6.2 Novartis Main Business
5.6.3 Novartis Anti-Diabetic Drugs Products, Services and Solutions
5.6.4 Novartis Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.6.5 Novartis Recent Developments
5.7 Novo Nordisk
5.7.1 Novo Nordisk Profile
5.7.2 Novo Nordisk Main Business
5.7.3 Novo Nordisk Anti-Diabetic Drugs Products, Services and Solutions
5.7.4 Novo Nordisk Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.7.5 Novo Nordisk Recent Developments
5.8 Sanofi
5.8.1 Sanofi Profile
5.8.2 Sanofi Main Business
5.8.3 Sanofi Anti-Diabetic Drugs Products, Services and Solutions
5.8.4 Sanofi Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.8.5 Sanofi Recent Developments
5.9 Teva Pharmaceutical Industries
5.9.1 Teva Pharmaceutical Industries Profile
5.9.2 Teva Pharmaceutical Industries Main Business
5.9.3 Teva Pharmaceutical Industries Anti-Diabetic Drugs Products, Services and Solutions
5.9.4 Teva Pharmaceutical Industries Anti-Diabetic Drugs Revenue (US$ Million) & (2018-2023)
5.9.5 Teva Pharmaceutical Industries Recent Developments
6 North America
6.1 North America Anti-Diabetic Drugs Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Anti-Diabetic Drugs Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Anti-Diabetic Drugs Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Anti-Diabetic Drugs Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Anti-Diabetic Drugs Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Anti-Diabetic Drugs Market Dynamics
11.1 Anti-Diabetic Drugs Industry Trends
11.2 Anti-Diabetic Drugs Market Drivers
11.3 Anti-Diabetic Drugs Market Challenges
11.4 Anti-Diabetic Drugs Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
